Sun Wants To Join The Biosimilars Party, In Time
Executive Summary
India's Sun Pharma is to foray into biosimilars, targeting first approval status for “third wave” products. It trails several peers and the changed stance comes as biosimilars gain traction in markets including the US, where experts have predicted a “coming out party” in the next few years.
You may also be interested in...
More Indian Firms Dip Toes In Vaccines Segment: Just 'Opportunistic'?
The vaccines segment continues to draw the interest of participants beyond those firms with a traditional core presence, with new players largely building partnered capabilities around COVID-19 inoculations. Are these merely opportunistic forays or will the competitive landscape for vaccines stand altered more widely?
More Indian Firms Dip Toes In Vaccines Segment: Just 'Opportunistic'?
The vaccines segment continues to draw the interest of participants beyond those firms with a traditional core presence, with new players largely building partnered capabilities around COVID-19 inoculations. Are these merely opportunistic forays or will the competitive landscape for vaccines stand altered more widely?.
Can Sun’s Novel Partnered Topical Drug Alter Acne Options?
Sun-Cassiopea’s novel mechanism of action acne drug sees a “fair degree” of early physician interest in the US, with some analysts expecting the topical androgen receptor inhibitor to emerge as a key addition to the Indian’s firm’s specialty portfolio.